Free Trial
NASDAQ:ESPR

Esperion Therapeutics (ESPR) Stock Price, News & Analysis

Esperion Therapeutics logo
$3.10 -0.03 (-0.80%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Esperion Therapeutics Stock (NASDAQ:ESPR)

Advanced

Key Stats

Today's Range
$3.03
$3.16
50-Day Range
$1.40
$3.30
52-Week Range
$0.69
$3.94
Volume
4.14 million shs
Average Volume
5.16 million shs
Market Capitalization
$624.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
Consensus Rating
Moderate Buy

Company Overview

Esperion Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
77th Percentile Overall Score

ESPR MarketRank™: 

Esperion Therapeutics scored higher than 77% of companies evaluated by MarketBeat, and ranked 242nd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Esperion Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Esperion Therapeutics has a consensus price target of $7.00, representing about 126.2% upside from its current price of $3.10.

  • Amount of Analyst Coverage

    Esperion Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Esperion Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Esperion Therapeutics are expected to grow in the coming year, from ($0.29) to ($0.13) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Esperion Therapeutics is -6.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Esperion Therapeutics is -6.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Esperion Therapeutics has a PEG Ratio of 55.59. PEG Ratios above 1 indicate that a company could be overvalued.

  • Read more about Esperion Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    12.59% of the float of Esperion Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Esperion Therapeutics has a short interest ratio ("days to cover") of 4.6.
  • Change versus previous month

    Short interest in Esperion Therapeutics has recently increased by 10.96%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Esperion Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Esperion Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.59% of the float of Esperion Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Esperion Therapeutics has a short interest ratio ("days to cover") of 4.6.
  • Change versus previous month

    Short interest in Esperion Therapeutics has recently increased by 10.96%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Esperion Therapeutics has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Esperion Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    20 people have searched for ESPR on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Esperion Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Esperion Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $38,833.00 in company stock.

  • Percentage Held by Insiders

    Only 1.70% of the stock of Esperion Therapeutics is held by insiders.

  • Percentage Held by Institutions

    47.39% of the stock of Esperion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Esperion Therapeutics' insider trading history.
Receive ESPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ESPR Stock News Headlines

Arizona-made nanochips the new millionaire maker?
George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the last 40 years. Now he's stepping forward with an even bigger prediction about what's being built in the Arizona desert. He believes 3 little-known companies will explode when a bombshell announcement just days from now. Smart investors are already positioning themselves.tc pixel
See More Headlines

ESPR Stock Analysis - Frequently Asked Questions

Esperion Therapeutics' stock was trading at $2.20 at the beginning of the year. Since then, ESPR shares have increased by 40.7% and is now trading at $3.0950.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) announced its earnings results on Tuesday, August, 5th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.15. The biopharmaceutical company earned $82.39 million during the quarter, compared to analyst estimates of $62.55 million.
Read the conference call transcript
.

Esperion Therapeutics' top institutional investors include Sanders Morris Harris LLC (0.01%). Insiders that own company stock include Benjamin Halladay, Benjamin Looker, Sheldon L Koenig, Eric Warren, Joanne M Foody and J Martin Carroll.
View institutional ownership trends
.

Shares of ESPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Esperion Therapeutics investors own include Humana (HUM), Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Marinus Pharmaceuticals (MRNS) and AU Optronics (AUOTY).

Company Calendar

Last Earnings
8/05/2025
Today
10/07/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ESPR
CIK
1434868
Fax
N/A
Employees
200
Year Founded
2008

Price Target and Rating

High Price Target
$16.00
Low Price Target
$3.00
Potential Upside/Downside
+128.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.49)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
55.59
Net Income
-$51.74 million
Net Margins
-35.84%
Pretax Margin
-38.80%
Return on Equity
N/A
Return on Assets
-28.41%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.15
Quick Ratio
0.76

Sales & Book Value

Annual Sales
$332.31 million
Price / Sales
1.86
Cash Flow
$0.02 per share
Price / Cash Flow
137.35
Book Value
($1.97) per share
Price / Book
-1.56

Miscellaneous

Outstanding Shares
201,620,000
Free Float
198,195,000
Market Cap
$617.97 million
Optionable
Optionable
Beta
0.96

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:ESPR) was last updated on 10/7/2025 by MarketBeat.com Staff
From Our Partners